08-11-2017 07:59 PM CET - Health & Medicine
Print

Global Myasthenia Gravis Market Size, Technological Advancements, Rising Geriatric Population, Trends & Forecasts (2017-2021)

Press release from: MarketResearchReports.biz

The report titled Global Myasthenia Gravis Market: Size, Trends & Forecasts (2017-2021) provides a detailed analysis of the myasthenia gravis market with description of market size and growth. The analysis includes market size in terms of value, and market share on the basis of therapy, by cases and by severity.

The report also provides a brief regional analysis of the US. The analysis includes market size in terms of number of patients on the basis of types of myasthenia gravis. Geographically, the Americas were the largest market and is expected to dominate the market in the forecasted period also. The growth in the market is estimated on the back of rising elderly population in the region.

Request to get the sample copy of this report : www.marketresearchreports.biz/sample/sample/1293481

Furthermore, the report also assesses the key opportunities available in the market and outlines the market dynamics that are and will be accountable for growth of the industry. Growth of the global myasthenia gravis market has also been forecasted for the period 2017-2021, taking into consideration previous growth outlines, growth drivers and the existing and forthcoming trends.

Some of the prominent players of the market include Avadel Pharmaceuticals, Hoffmann-La Roche, Pfizer, and Argenx. A brief company profiling of these major players have also been provided in the report on the basis of aspects like business overview, financial overview and business strategies adopted by respective companies.

Company Coverage

Avadel Pharmaceuticals
F. Hoffmann-La Roche
Pfizer
Argenx

Region Coverage

The US

Browse Full Report : www.marketresearchreports.biz/reports/1293481/global-myas...

Executive Summary

Myasthenia gravis is a chronic neuromuscular disease that leads to weakness in the skeletal muscles, which help in the breathing and movement of the body parts including the arms and legs. The word myasthenia gravis has Latin and Greek origin and means serious muscle weakness. Myasthenia Gravis is rare and only affects 14 to 20 people out of every 100,000. The main symptom of myasthenia gravis is weakness in the voluntary skeletal muscles, which are muscles under ones control. Weakness associated with MG typically gets worse with more activity and improves with rest.

The disease is categorized into six types namely: Early-Onset MG, Late-Onset MG, Thymoma-Associated MG, MG with Anti-Musk Antibodies, Ocular MG, and MG with no detectable AChR and MuSK Antibodies. Myasthenia gravis is caused by an error in the transmission of nerve impulses to muscles. Major treatments available for MG are Symptomatic Treatment, Rapid Short-Term Immune-Modulating Treatment, Chronic Long-Term Immune-Modulating Treatment and Surgery.

Send An Enquiry : www.marketresearchreports.biz/sample/enquiry/1293481

The global myasthenia gravis market has increased over the past few years and projections are made that the market would rise in the forecasted period i.e. 2017 to 2021 at a significant growth rate. The global myasthenia gravis market is expected to boost by the major factors such as rising geriatric population, technological advancements, approval of monoclonal antibodies, strategies such as mergers and acquisitions etc. Yet the market growth is restrain by some challenges such as competition from off-label drugs, limited availability of FDA approved drugs, high cost of the treatment etc.

MRRbiz supports your business intelligence needs with over 700,000 market research reports, company profiles, data books, and regional market data sheets in its repository. Our document database is updated by the hour, which means that you always have access to fresh data spanning over 300 industries and their sub-segments.

State Tower
90 State Street, Suite 700
Albany, NY 12207
United States

Toll Free: 866-997-4948
(USA-Canada)

Tel: +1-518-621-2074
E: sales@marketresearchreports.biz

This release was published on openPR.
News-ID: 666726 • Views: 385
More releases More releases
Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.

You can edit or delete your press release here: